AstraZeneca: Hyperlipidemias trials

The registry lists 20 Hyperlipidemias studies with AstraZeneca as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 4Phase 3 4Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With HyperlipidaemiaCompletedNCT04964557Phase 2Results posted
• A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompletedNCT02434497Phase 3Results posted
• Rosuvastatin Adherence App Study in ChinaCompletedNCT02433288Not applicableResults posted
• A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompletedNCT02226198Phase 3Results posted
• [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROLCompletedNCT01408303Phase 3Results posted
• Epanova® for Lowering Very High TriglyceridesCompletedNCT01242527Phase 2/3Results posted
• Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic PatientsCompletedNCT00473655Phase 4Results posted
• Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal DiseaseCompletedNCT00296400Phase 2Results posted
• Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal DiseaseCompletedNCT00296374Phase 2Results posted
• A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy AdultsCompletedNCT07622433Phase 1
• A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy AdultsCompletedNCT07316608Phase 1
• Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).CompletedNCT00891124
• European Study of Cardiovascular RiskCompletedNCT00882336
• Management of Cardiovascular Risk FactorsCompletedNCT00848380
• Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment GoalCompletedNCT00781560
• To Explore the Treatment Effect of Various Commercially Available Statins on Patients With HyperlipidemiaCompletedNCT00726362
• C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched PatientsCompletedNCT00688454
• Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsCompletedNCT00536965
• Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsCompletedNCT00536796
• Diabetic Under 70 (Diabetics Below 70)CompletedNCT00516204